Xbrane Biopharma AB: Positive outcome of inspection from Italian Medicines Agency – GMP approval of Xbrane’s Spherotide production facility is expected in Q1 2017

Press release

2016-10-24

The positive outcome of the inspection of the production facility confirms Xbranes expectation of receiving GMP approval and to be able to ship its first commercial batch of Spherotide at a value of SEK 7 million in Q1 2017.

In August 2016 Xbranes fully owned subsidiary s (…)

Xbrane reaches commercial breakthrough with the first batches of Spherotide valued at SEK 7 million

Press release
2016-09-07

Xbrane has completed the production and performed quality control of the first commercial batches of Spherotide. The value of the produced batches is approximately SEK 7 million, according to an agreement with the company’s distribution partner in the Middle East.

Payment  (…)

Xbrane Biopharma AB (publ) releases interim report for the period April – June 2016

Press Release
2016-08-22

Xbrane Biopharma ABs interim report for the period April-June 2016 is now available on the Company’s website, www.xbrane.com.

Period April-June 2016

• Group net sales amounted to 1 032 017 (75 000) SEK
• Group total income amounted to 1 108 233 (85 512) SEK
• Earnings bef (…)

Xbrane Biopharma AB: Oxford Nanopore Technologies licenses Xbrane Biopharma’s protein production technology

Press Release
2016-08-08

Oxford Nanopore Technologies licenses Xbrane Biopharma’s protein production technology

Xbrane Biopharma AB has entered into a licence agreement with Oxford Nanopore Technologies regarding Xbrane’s technology for the production of proteins used within Oxford Nanopore Techno (…)

Xbrane Biopharma AB: Xbrane submits GMP approval application for the production facility for Spherotide according to time plan

Press Release
2016-08-01

Xbrane submits GMP approval application for the production facility for Spherotide according to time plan

Xbranes subsidiary Primm Pharma has, according to the time plan, submitted the application to AIFA, the Italian Medicines Agency, for GMP approval of its production fa (…)